Journal List > J Korean Ophthalmol Soc > v.51(2) > 1008731

Yoon and Park: Ahmed Valve Implantation with Adjunctive Mitomycin C and 5-Fluorouracil: Outcomes at One Year

Abstract

Purpose

To evaluate the outcome after Ahmed valve implantation in patients with neovascular glaucoma when using intraoperative mitomycin C (MMC) and postoperative 5-fluorouracil (5-FU).

Methods

A total of 40 eyes of 40 patients with neovascular glaucoma who received antiglacomatous medication without previous glaucoma surgery were included in the present study. The patients received Ahmed valve implantation and intraoperative MMC and postoperative 5-FU. Failure was defined as the first occurrence of any of the following: 1) the first of three consecutive visits where intraocular pressure (IOP) was >18 mmHg or 20% IOP reduction from baseline and the final number of topical medication did not reduce by at least two from baseline, 2) the need for additional surgery, or 3) the occurrence of a serious complication.

Results

The cumulative success rate was 77.5% at 12 months. The final number of topical medication after Ahmed valve implantation was 0.73±0.78, and the change in the number of medication from baseline was −2.18±0.84. Serious complications such as endophthalmitis, valve exposure or prolonged hypotony were not observed.

Conclusions

The adjunctive use of intraoperative MMC and postoperative 5-FU with Ahmed valve implantation results in a high success rate and good IOP control and did not show serious complications within the postoperative period.

References

1. Coleman AL, Hill R, Wilson MR, et al. Initial clinical experience with Ahmed glaucoma valve implant. Am J Ophthalmol. 1995; 120:23–31.
2. Allen RC, Bellow AR, Hutchinson BT. Filtration surgery in the treatment of neovascular glaucoma. Ophthalmology. 1982; 89:1181–7.
crossref
3. Sutton GE, Popp JC, Records RE. Krupin Denver valve and aberrations glaucoma. Trans Ophthalmol Soc U K. 1982; 102:119–21.
4. Lee SH, Ma KT, Hong YJ. Outcome of Ahmed Valve aberrations in Refractory Glaucoma. J Korean Ophthalmol Soc. 2007; 48:83–90.
5. Topouzis F, Coleman AL, Choplin N, et al. Follow-up of the original cohort with the Ahmed glaucoma valve implant. Am J Ophthalmol. 1999; 128:198–204.
6. Nouri-Mahdavi K, Caprioli J. Evaluation of the hypertensive phase after insertion of the Ahmed glaucoma valve. Am J Ophthalmol. 2003; 136:1001–8.
crossref
7. Susanna R, Nicolela MT, Takahashi WY. Mitomycin C as adjunctive therapy with glaucoma implant surgery. Ophthalmic Surg. 1994; 25:458–62.
crossref
8. Kook MS, Yoon J, Kim J, Lee MS. Clinical results of Ahmed glaucoma valve implantation in refractory glaucoma with adjunctive mitomycin C. Ophthalmic Surg Lasers. 2000; 31:100–6.
crossref
9. Kurnaz E, Kubaloglu A, Yilmaz Y, et al. The effect of adjunctive mitomycin C in Ahmed glaucoma valve implantation. Eur J Ophthalmol. 2005; 15:27–31.
crossref
10. Schwartz AL, Anderson RD. Trabecular surgery. Arch aberrations. 1974; 92:134–8.
crossref
11. Allen RC, Bellow AR, Hutchinson BT. Filtration surgery in the treatment of neovascular glaucoma. Ophthalmology. 1982; 89:1181–7.
crossref
12. Skuta GL, Parrish RK. Wound healing in glaucoma filtering surgery. Surv Ophthalmol. 1987; 32:149–70.
crossref
13. Lee JH, Kim SS, Hong YJ. A clinical study of the Ahmed glaucoma valve implant in refractory glaucoma. J Korean Ophthalmol Soc. 2001; 42:1003–10.
14. Ayyala RS, Zurakowski D, Smith JA, et al. A clinical study of the Ahmed glaucoma valve implant in advanced glaucoma. aberrationsogy. 1998; 105:1968–76.
15. Guo W, Song Y, Sun X. Ahmed valve Implantation for refractory glaucoma. Zhonghua Yan Ke Za Zhi. 1997; 33:417–20.
16. Yalvac IS, Eksioglu U, Santana B, Duman S. Long term results of Ahmed glaucoma valve and Molteno implant in neovascular glaucoma. Eye. 2007; 21:65–70.
17. Im YW, Lym HS, Park CK, Moon JI. Comparison of mitomycin trabeculectomy and Ahmed valve implant surgery for aberrations glaucoma. J Korean Ophthalmol Soc. 2004; 45:1515–21.
18. Lee JJ, Park KH, Kim DM, Kim TW. Clinical outcomes of aberrations glaucoma valve implantation using tube ligation and removable external stents. Korean J Ophthalmol. 2009; 23:86–92.
19. Alvarado JA, Hollander DA, Juster RP, Lee LC. Ahmed valve implantation with adjunctive mitomycin C and 5-fluorouracil: long-term outcomes. Am J Ophthalmol. 2008; 146:276–84.
crossref
20. Wilson MR, Mendis U, Paliwal A, Haynatzka V. Long-term follow-up of primary glaucoma surgery with Ahmed glaucoma valve implant versus trabeculectomy. Am J Ophthalmol. 2003; 136:464–70.
crossref
21. Souza C, Tran DH, Loman J, et al. Long-term outcomes of Ahmed glaucoma valve implantation in refractory glaucoma. Am J Ophthalmol. 2007; 144:893–900.
22. Trigler L, Proia AD, Freedman SF. Fibrovascular ingrowths as a cause of Ahmed glaucoma valve failure in children. Am J aberrations. 2006; 141:388–9.
23. Hill RA, Pilouzian A, Liaw L. Pathophysiology of and aberrations against late Ahmed glaucoma valve occlusion. Am J aberrations. 2000; 129:608–12.

Figure 1.
Intraocular pressure (IOP) following Ahmed valve implantation with adjunctive intraoperative mitomycin C (MMC) and postoperative 5-fluorouracil (5-FU). *D=day W=week; M=month.
jkos-51-227f1.tif
Figure 2.
Kaplan-Meier estimates of the cumulative probability of valve success for Ahmed valve implanted eyes. Failure was defined as the first occurrence following an initial postoperative period of any of the following events: 1) IOP >18 mmHg for three consecutive visits or <20% IOP reduction from baseline and the final number of topical medications was not reduced by at least two from baseline, 2) need for additional surgery to repair a malfunctioning Ahmed valve, or 3) serious postoperative complication.
jkos-51-227f2.tif
Table 1.
Baseline characteristics for Ahmed valve-implanted eyes
Ahmed valve implanted eyes (n=40)
Age (Mean± SD) 54.80±9.51
Sex, n (%)
   Male 21 (53.0%)
   Female 19 (47.7%)
Diagnosis, n (%)
   NVG 40 (100.0%)
Lens status, n (%)
   Aphakic 3 (7.5%)
   Phakic 19 (47.5%)
   Pseudophakic 18 (45.0%)
Previous glaucoma surgery
   No 40 (100%)
Preoperative IOP (Mean± SD) mmHg 38.80±5.53
No. of preoperative medication (Mean± SD) 2.95±0.71
MMC time (minute) 5.75±0.95
No. of 5-FU injections (Mean± SD) 4.07±0.65
Follow up period (Mean± SD, months) 16.8±3.73

* NVG=neovascular glaucoma

MMC=mitomycin C

5-FU=5-fluorouracil.

Table 2.
Postoperative intraocular pressure for Ahmed valve implanted eyes during the follow-up period
Time IOP (Mean± SD) (mmHg)
Baseline 38.80±5.53
1 day 13.27±2.68
1 week 13.42±2.37
1 month 14.15±1.79
3 months 14.65±2.05
6 months 15.13±3.40
9 months 15.03±5.11
12 months 14.65±5.28
Table 3.
Kaplan-Meier estimates of probability of success in Ahmed valve implanted eyes
Month Ahmed valve implanted eyes (n=40)
postoperative Survival proportion (Standard error)
1 0.975 (0.024)
2 0.900 (0.047)
3 0.825 (0.060)
6 0.800 (0.063)
9 0.775 (0.066)
12 0.775 (0.066)
Table 4.
Postoperative characteristics of Ahmed valve implanted eyes
Ahmed valve implanted eyes (n=40)
Hypertensive phase
 Yes 9.00 (22.5%)
Postoperative no. of medications
 Mean (SD) 0.78 (0.73)
Change in no. of medication from baseline
 Mean (SD) −2.18 (0.84)
Medications relative to baseline
 Lower no. of medications 38 (95%)
 Same no. of medications 2 (5%)
 Greater no. of medications 0
Table 5.
Postoperative complication for Ahmed valve implanted eyes
Ahmed valve implanted eyes (n=40)
Transient hypotony 2 (5.0%)
Transient hyphema 3 (7.5%)
Retration of tube from anterior chamber 2 (5.5%)
Table 6.
Previous published estimated probability of valve success from studies of Ahmed valve implantation alone for neovascular glaucoma
Postoperative Year
1 st year
Sang Hyup Lee and associates4 0.51
Guo W and associates15 0.40
I.S. Yalvac and associates16 0.63
Yong Woo Im and associates17 0.42
Jong Joo Lee and associates18 0.30
TOOLS
Similar articles